Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.
Fei Chen
Advertisement
Fei Chen, PhD, is head, Cell Line Development, at WuXi Biologics.
Articles by Fei Chen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
5